De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics.
In developed countries, most people living with HIV/AIDS are treated with costly brand single-tablet regimens. Given the economic impact, French guidelines recommend using generic antiretroviral therapy when possible to decrease antiretroviral therapy costs. We aimed to study HIV-infected patients...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0239704 |
id |
doaj-d7aa8070d6c848c9b6dd905c8f6fef8f |
---|---|
record_format |
Article |
spelling |
doaj-d7aa8070d6c848c9b6dd905c8f6fef8f2021-03-03T22:07:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01159e023970410.1371/journal.pone.0239704De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics.Jean-Stephane GiraudMelanie DoisneAurelie Chan Hew WaiCatherine MajerholcErwan FournKarine SejeanJulie TrichereauBrigitte BonanDavid ZucmanIn developed countries, most people living with HIV/AIDS are treated with costly brand single-tablet regimens. Given the economic impact, French guidelines recommend using generic antiretroviral therapy when possible to decrease antiretroviral therapy costs. We aimed to study HIV-infected patients' acceptability to switch from a brand single-tablet regimens [abacavir/lamivudine/dolutegravir (Triumeq®) or emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera®)] to a treatment comprising of two pills: one is a fixed-dose generic combination of 2 Nucleoside Analogs and the second tablet is the third antiretroviral. This study was a prospective observational study in a French hospital. During their follow-up, patients on stable single-tablet regimens were made aware of the possible cost-saving. They were questioned about their willingness and barriers accepting the substitution. Participants chose between the two regimens, either to remain on single-tablet regimens or switch to the de-simplified regimen. Six months later, a second survey was given to the patient who chose to de-simplify and HIV viral load was controlled. The study included 98 patients: 60 receiving emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera®) and 38 on abacavir/lamivudine/dolutegravir (Triumeq®). Forty-five patients accepted the de-simplified treatment, 37 refused and 16 were undecided and followed the decision offered by their physician. The main reason for unwillingness to switch is the number of pills (77.3%). In multivariate model analysis, male patients (p = 0.001) who have taken antiretroviral therapy for over 20 years (p = 0.04) and who retrieve their treatment in their community hospital (p = 0.03) are more likely to accept the switch. Fifty-one patients accepted to replace their single-tablet regimens and six months later, the majority was satisfied; only four returned to single-tablet regimens because of suspected side effects. Half of the people living with HIV/AIDS in our cohort accepted to switch from brand single-tablet regimens to a two-tablet regimen containing generic drugs within a process that emphasizes health expenditure savings.https://doi.org/10.1371/journal.pone.0239704 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jean-Stephane Giraud Melanie Doisne Aurelie Chan Hew Wai Catherine Majerholc Erwan Fourn Karine Sejean Julie Trichereau Brigitte Bonan David Zucman |
spellingShingle |
Jean-Stephane Giraud Melanie Doisne Aurelie Chan Hew Wai Catherine Majerholc Erwan Fourn Karine Sejean Julie Trichereau Brigitte Bonan David Zucman De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics. PLoS ONE |
author_facet |
Jean-Stephane Giraud Melanie Doisne Aurelie Chan Hew Wai Catherine Majerholc Erwan Fourn Karine Sejean Julie Trichereau Brigitte Bonan David Zucman |
author_sort |
Jean-Stephane Giraud |
title |
De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics. |
title_short |
De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics. |
title_full |
De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics. |
title_fullStr |
De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics. |
title_full_unstemmed |
De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics. |
title_sort |
de-simplifying single-tablet antiretroviral treatments for cost savings in france: from the patient perspectives to a 6-month follow-up on generics. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2020-01-01 |
description |
In developed countries, most people living with HIV/AIDS are treated with costly brand single-tablet regimens. Given the economic impact, French guidelines recommend using generic antiretroviral therapy when possible to decrease antiretroviral therapy costs. We aimed to study HIV-infected patients' acceptability to switch from a brand single-tablet regimens [abacavir/lamivudine/dolutegravir (Triumeq®) or emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera®)] to a treatment comprising of two pills: one is a fixed-dose generic combination of 2 Nucleoside Analogs and the second tablet is the third antiretroviral. This study was a prospective observational study in a French hospital. During their follow-up, patients on stable single-tablet regimens were made aware of the possible cost-saving. They were questioned about their willingness and barriers accepting the substitution. Participants chose between the two regimens, either to remain on single-tablet regimens or switch to the de-simplified regimen. Six months later, a second survey was given to the patient who chose to de-simplify and HIV viral load was controlled. The study included 98 patients: 60 receiving emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera®) and 38 on abacavir/lamivudine/dolutegravir (Triumeq®). Forty-five patients accepted the de-simplified treatment, 37 refused and 16 were undecided and followed the decision offered by their physician. The main reason for unwillingness to switch is the number of pills (77.3%). In multivariate model analysis, male patients (p = 0.001) who have taken antiretroviral therapy for over 20 years (p = 0.04) and who retrieve their treatment in their community hospital (p = 0.03) are more likely to accept the switch. Fifty-one patients accepted to replace their single-tablet regimens and six months later, the majority was satisfied; only four returned to single-tablet regimens because of suspected side effects. Half of the people living with HIV/AIDS in our cohort accepted to switch from brand single-tablet regimens to a two-tablet regimen containing generic drugs within a process that emphasizes health expenditure savings. |
url |
https://doi.org/10.1371/journal.pone.0239704 |
work_keys_str_mv |
AT jeanstephanegiraud desimplifyingsingletabletantiretroviraltreatmentsforcostsavingsinfrancefromthepatientperspectivestoa6monthfollowupongenerics AT melaniedoisne desimplifyingsingletabletantiretroviraltreatmentsforcostsavingsinfrancefromthepatientperspectivestoa6monthfollowupongenerics AT aureliechanhewwai desimplifyingsingletabletantiretroviraltreatmentsforcostsavingsinfrancefromthepatientperspectivestoa6monthfollowupongenerics AT catherinemajerholc desimplifyingsingletabletantiretroviraltreatmentsforcostsavingsinfrancefromthepatientperspectivestoa6monthfollowupongenerics AT erwanfourn desimplifyingsingletabletantiretroviraltreatmentsforcostsavingsinfrancefromthepatientperspectivestoa6monthfollowupongenerics AT karinesejean desimplifyingsingletabletantiretroviraltreatmentsforcostsavingsinfrancefromthepatientperspectivestoa6monthfollowupongenerics AT julietrichereau desimplifyingsingletabletantiretroviraltreatmentsforcostsavingsinfrancefromthepatientperspectivestoa6monthfollowupongenerics AT brigittebonan desimplifyingsingletabletantiretroviraltreatmentsforcostsavingsinfrancefromthepatientperspectivestoa6monthfollowupongenerics AT davidzucman desimplifyingsingletabletantiretroviraltreatmentsforcostsavingsinfrancefromthepatientperspectivestoa6monthfollowupongenerics |
_version_ |
1714813399693524992 |